BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gemcitabine (FF-10832) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Gemcitabine (FF-10832)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05318573-2482@assetmemo.bio
DTSTAMP:20261121T005736Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Gemcitabine (FF-10832): Phase 2 readout est. (NCT05318573)
DESCRIPTION:Gemcitabine (FF-10832)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Evaluate Safety\, Efficacy of FF-10832 in Combo With Pe
 mbrolizumab in Urothelial & Non-small Cell Lung Cancer\nEstimated primary 
 completion: May 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /gemcitabine-ff-10832#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05318573
URL:https://assetmemo.bio/drug/gemcitabine-ff-10832#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
